1.06 USD
▲+0.02+1.92%
盘后 1.02 -3.43%
2026-11-19
市值
$314.48M
市盈率
—
EPS
-0.61
股息率
—
52 周区间
0.87 – 2.65
成交量
1.65M
Beta
1.90
目标价
6.50
52W 低 0.8752W 高 2.65
价格走势
公司简介
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, a...